WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs™) Data Selected for Poster Presentation at 61st American Society of Hematology Annual Meeting and Exposition
BALTIMORE and PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that data demonstrating the efficacy of chimeric antigen receptor (CAR) T cells developed using MILs (CAR-MILs) in comparison to peripheral blood lymphocytes has been selected for a poster at 61st American Society of Hematology (ASH) Annual Meeting and Exposition. ASH 2019 will be held December 7-10 at the Orange County Convention Center in Orlando, FL.
Details of the presentation are as follows:
Title: Superior efficacy of CAR-T cells using marrow-infiltrating lymphocytes (MILs™) as compared to peripheral blood lymphocytes (PBLs)
Abstract number: 4437
Session name: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster III
Date and time: Monday, December 9, 2019 at 6–8 p.m. ET
Location: Orange County Convention Center, Hall B
Presenter: Eric Lutz, Ph.D., director of research, WindMIL Therapeutics
A copy of the abstract can be viewed online through the ASH website.
About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence. For more information, please visit: https://windmiltx.com.
Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
gcestari@6degreespr.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
